LEXX
Lexaria Bioscience Corp.
Price Chart
Latest Quote
$0.55
+0.00 (+0.55%)
Current Price
| Previous Close | $0.55 |
| Open | $0.54 |
| Day High | $0.57 |
| Day Low | $0.54 |
| Volume | 55,287 |
Stock Information
| Shares Outstanding | 24.79M |
| Total Debt | $94K |
| Cash Equivalents | $5.27M |
| Revenue | $368K |
| Net Income | $-9.53M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $13.63M |
| EPS (TTM) | $-0.47 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $7.99M |
| Sales | $368K |
| Income | $-9.53M |
| Book/sh | $0.27 |
| Cash/sh | $0.21 |
| Employees | 7 |
Financial Ratios
| Quick Ratio | 24.74 |
| Current Ratio | 26.88 |
| Debt/Eq | 1.52 |
Returns & Margins
| ROA | -75.98% |
| ROE | -147.07% |
| Gross Margin | 100.00% |
| Operating Margin | -7259.52% |
Ownership
| Insider Ownership | 5.74% |
| Institutional Ownership | 6.01% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.41 |
| P/S | 37.05 |
| P/B | 2.08 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $3.75 |
Technical Indicators
| SMA20 | $0.61 |
| SMA50 | $0.69 |
| SMA200 | $0.84 |
| RSI | 34.97 |
| ATR | 0.0498 |
| Shares Float | 24.04M |
| Short Float | 1.47% |
| Short Ratio | 2.11 |
| Volatility | 0.33 |
| Rel Volume | 0.71 |
Performance History
| Week | -9.98% |
| Month | -17.29% |
| Quarter | -29.03% |
| 6 Months | -18.40% |
| YTD | -15.90% |
| Year | -42.11% |
| 3 Years | -24.76% |
| 5 Years | -92.01% |
| 10 Years | -87.72% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $0.55 | 55,287 |
| 2026-06-24 | $0.55 | 90,800 |
| 2026-06-23 | $0.57 | 49,400 |
| 2026-06-22 | $0.58 | 62,900 |
| 2026-06-18 | $0.54 | 150,700 |
| 2026-06-17 | $0.61 | 62,900 |
| 2026-06-16 | $0.59 | 46,900 |
| 2026-06-15 | $0.61 | 34,400 |
| 2026-06-12 | $0.62 | 96,200 |
| 2026-06-11 | $0.64 | 71,100 |
| 2026-06-10 | $0.66 | 117,000 |
| 2026-06-09 | $0.67 | 110,700 |
| 2026-06-08 | $0.65 | 41,100 |
| 2026-06-05 | $0.64 | 54,900 |
| 2026-06-04 | $0.64 | 147,300 |
| 2026-06-03 | $0.62 | 59,700 |
| 2026-06-02 | $0.60 | 98,600 |
| 2026-06-01 | $0.62 | 51,100 |
| 2026-05-29 | $0.60 | 61,800 |
| 2026-05-28 | $0.62 | 98,500 |
| 2026-05-27 | $0.61 | 79,300 |
| 2026-05-26 | $0.67 | 125,000 |
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. The company's DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, epilepsy, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, and oral products; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
đ° Latest News
Lexaria Bioscience (NASDAQ:LEXX) Will Have To Spend Its Cash Wisely
Simply Wall St. âĸ 2026-04-15T10:25:11Z
Lexaria releases additional results from Phase 1b study GLP-1-H24-4
TipRanks âĸ 2025-12-31T14:25:09Z
Lexaria Bioscience Corp. (NASDAQ:LEXX): Are Analysts Optimistic?
Simply Wall St. âĸ 2025-11-29T13:20:45Z
Lexaria Bioscience announces last patient, last visit in Phase 1b GLP-1 study
TipRanks âĸ 2025-08-15T13:25:37Z
Lexaria Bioscience Third Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Simply Wall St. âĸ 2025-07-16T10:08:20Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $2,720 | $4,822 | $31,500 | $71,841 |
| Cost Of Revenue | $2,720 | $4,822 | $31,500 | $71,841 |
| Total Revenue | $705,923 | $464,278 | $226,208 | $255,397 |
| Operating Revenue | $705,923 | $463,378 | $190,967 | $167,998 |
| Expenses | ||||
| Total Expenses | $12,586,660 | $6,217,408 | $6,760,230 | $6,874,436 |
| Other Income Expense | $-33,714 | $-69,835 | $-221,693 | $-764,614 |
| Net Non Operating Interest Income Expense | $3,017 | $14,311 | $43,190 | $0 |
| Operating Expense | $12,583,940 | $6,212,586 | $6,728,730 | $6,802,595 |
| General And Administrative Expense | $4,345,183 | $3,852,021 | $3,062,009 | $4,959,920 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-11,901,841 | $-5,795,345 | $-6,664,899 | $-7,269,324 |
| Net Interest Income | $3,017 | $14,311 | $43,190 | $0 |
| Interest Income | $3,017 | $14,311 | $43,190 | $0 |
| Normalized Income | $-11,868,127 | $-5,725,510 | $-6,443,206 | $-6,504,710 |
| Net Income From Continuing And Discontinued Operation | $-11,901,841 | $-5,795,345 | $-6,664,899 | $-7,269,324 |
| Total Operating Income As Reported | $-11,880,737 | $-5,753,130 | $-6,534,022 | $-6,619,039 |
| Net Income Common Stockholders | $-11,901,841 | $-5,795,345 | $-6,664,899 | $-7,269,324 |
| Net Income | $-11,901,841 | $-5,795,345 | $-6,664,899 | $-7,269,324 |
| Net Income Including Noncontrolling Interests | $-11,911,434 | $-5,808,654 | $-6,712,525 | $-7,383,653 |
| Net Income Continuous Operations | $-11,911,434 | $-5,808,654 | $-6,712,525 | $-7,383,653 |
| Pretax Income | $-11,911,434 | $-5,808,654 | $-6,712,525 | $-7,383,653 |
| Interest Income Non Operating | $3,017 | $14,311 | $43,190 | $0 |
| Operating Income | $-11,880,737 | $-5,753,130 | $-6,534,022 | $-6,619,039 |
| Gross Profit | $703,203 | $459,456 | $194,708 | $183,556 |
| Net Income Discontinuous Operations | - | - | - | $0 |
| Special Income Charges | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-0.66 | $-0.47 | $-1.01 | $-1.24 |
| Basic EPS | $-0.66 | $-0.47 | $-1.01 | $-1.24 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-11,759,198 | $-5,607,142 | $-6,166,932 | $-5,751,707 |
| Total Unusual Items | $-33,714 | $-69,835 | $-221,693 | $-764,614 |
| Total Unusual Items Excluding Goodwill | $-33,714 | $-69,835 | $-221,693 | $-764,614 |
| Reconciled Depreciation | $87,825 | $76,153 | $145,397 | $102,718 |
| EBITDA (Bullshit earnings) | $-11,792,912 | $-5,676,977 | $-6,388,625 | $-6,516,321 |
| EBIT | $-11,880,737 | $-5,753,130 | $-6,534,022 | $-6,619,039 |
| Diluted Average Shares | $17,998,715 | $12,383,974 | $6,614,066 | $5,885,245 |
| Basic Average Shares | $17,998,715 | $12,383,974 | $6,614,066 | $5,885,245 |
| Diluted NI Availto Com Stockholders | $-11,901,841 | $-5,795,345 | $-6,664,899 | $-7,269,324 |
| Minority Interests | $9,593 | $13,309 | $47,626 | $114,329 |
| Gain On Sale Of Security | $-33,714 | $-69,835 | $-221,693 | $-764,614 |
| Research And Development | $8,238,757 | $2,360,565 | $3,666,721 | $1,842,675 |
| Selling General And Administration | $4,345,183 | $3,852,021 | $3,062,009 | $4,959,920 |
| Other Gand A | $4,345,183 | $3,852,021 | $3,062,009 | $4,959,920 |
| Gain On Sale Of Ppe | - | - | - | $0 |
Fetched: 2026-06-24
Balance Sheet (Annual)
| Metric | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $2,681,879 | $7,519,724 | $2,581,493 | $7,460,442 |
| Total Assets | $4,175,121 | $8,867,789 | $3,083,986 | $7,833,927 |
| Total Non Current Assets | $706,776 | $969,803 | $932,773 | $856,411 |
| Non Current Accounts Receivable | $64,013 | $63,575 | $48,559 | - |
| Goodwill And Other Intangible Assets | $307,818 | $516,676 | $462,625 | $488,462 |
| Other Intangible Assets | $307,818 | $516,676 | $462,625 | $488,462 |
| Current Assets | $3,468,345 | $7,897,986 | $2,151,213 | $6,977,516 |
| Prepaid Assets | $1,132,504 | $1,187,817 | $546,783 | $576,761 |
| Receivables | $368,358 | $154,477 | $126,686 | $201,784 |
| Other Receivables | $174,000 | $84,000 | $24,635 | $37,248 |
| Taxes Receivable | $194,358 | $70,477 | $102,051 | $84,162 |
| Cash Cash Equivalents And Short Term Investments | $1,967,483 | $6,555,692 | $1,477,744 | $6,160,553 |
| Cash And Cash Equivalents | $1,802,123 | $6,499,885 | $1,352,102 | $5,813,218 |
| Cash Financial | $1,802,123 | $6,499,885 | $1,352,102 | $5,813,218 |
| Inventory | - | - | $0 | $38,418 |
| Accounts Receivable | - | - | $48,559 | $80,374 |
| Debt | ||||
| Total Debt | $109,320 | $137,366 | $163,967 | $49,988 |
| Long Term Debt And Capital Lease Obligation | $78,903 | $109,319 | $136,173 | $7,401 |
| Current Debt And Capital Lease Obligation | $30,417 | $28,047 | $27,794 | $42,587 |
| Current Debt | - | - | - | - |
| Other Current Borrowings | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,572,366 | $1,208,738 | $403,908 | $201,437 |
| Total Non Current Liabilities Net Minority Interest | $78,903 | $109,319 | $136,173 | $7,401 |
| Current Liabilities | $1,493,463 | $1,099,419 | $267,735 | $194,036 |
| Current Deferred Liabilities | $0 | $4,963 | $0 | - |
| Payables And Accrued Expenses | $1,463,046 | $1,066,409 | $239,941 | $151,449 |
| Payables | $1,463,046 | $1,066,409 | $239,941 | $151,449 |
| Other Payable | $76,496 | - | - | $62,996 |
| Total Tax Payable | $21,506 | $8,528 | $14,903 | $31,303 |
| Accounts Payable | $1,365,044 | $1,057,881 | $225,038 | $120,146 |
| Income Tax Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $2,989,697 | $8,036,400 | $3,044,118 | $7,948,904 |
| Total Equity Gross Minority Interest | $2,602,755 | $7,659,051 | $2,680,078 | $7,632,490 |
| Stockholders Equity | $2,989,697 | $8,036,400 | $3,044,118 | $7,948,904 |
| Gains Losses Not Affecting Retained Earnings | $-70,335 | $-19,816 | $0 | - |
| Other Equity Adjustments | $-70,335 | $-19,816 | - | - |
| Retained Earnings | $-63,460,613 | $-51,558,772 | $-45,763,427 | $-39,098,528 |
| Other | ||||
| Ordinary Shares Number | $19,559,179 | $15,810,205 | $8,091,650 | $5,950,998 |
| Share Issued | $19,559,179 | $15,810,205 | $8,091,650 | $5,950,998 |
| Tangible Book Value | $2,681,879 | $7,519,724 | $2,581,493 | $7,460,442 |
| Invested Capital | $2,989,697 | $8,036,400 | $3,044,118 | $7,948,904 |
| Working Capital | $1,974,882 | $6,798,567 | $1,883,478 | $6,783,480 |
| Capital Lease Obligations | $109,320 | $137,366 | $163,967 | $49,988 |
| Total Capitalization | $2,989,697 | $8,036,400 | $3,044,118 | $7,948,904 |
| Minority Interest | $-386,942 | $-377,349 | $-364,040 | $-316,414 |
| Additional Paid In Capital | $66,501,086 | $59,599,178 | $48,799,454 | $47,041,481 |
| Capital Stock | $19,559 | $15,810 | $8,091 | $5,951 |
| Common Stock | $19,559 | $15,810 | $8,091 | $5,951 |
| Long Term Capital Lease Obligation | $78,903 | $109,319 | $136,173 | $7,401 |
| Current Deferred Revenue | $0 | $4,963 | $0 | - |
| Current Capital Lease Obligation | $30,417 | $28,047 | $27,794 | $42,587 |
| Net PPE | $334,945 | $389,552 | $421,589 | $367,949 |
| Accumulated Depreciation | $-568,843 | $-517,616 | $-475,168 | $-379,993 |
| Gross PPE | $903,788 | $907,168 | $896,757 | $747,942 |
| Leases | $259,981 | $259,981 | $259,981 | $259,981 |
| Other Properties | $541,900 | $545,280 | $534,869 | $386,054 |
| Machinery Furniture Equipment | $101,907 | $101,907 | $101,907 | $101,907 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $165,360 | $55,807 | $125,642 | $347,335 |
| Raw Materials | - | - | $0 | $38,418 |
| Dueto Related Parties Current | - | - | - | - |
Fetched: 2026-06-24
Cash Flow Statement (Annual)
| Metric | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-10,550,139 | $-5,147,608 | $-6,050,847 | $-5,059,979 |
| Operating Activities | ||||
| Operating Cash Flow | $-10,450,387 | $-4,959,003 | $-5,881,237 | $-4,879,339 |
| Cash Flow From Continuing Operating Activities | $-10,450,387 | $-4,959,003 | $-5,881,237 | $-4,879,339 |
| Operating Gains Losses | - | - | - | $-7,926 |
| Investing Activities | ||||
| Capital Expenditure | $-99,752 | $-188,605 | $-169,610 | $-180,640 |
| Investing Cash Flow | $-243,019 | $-188,605 | $-169,610 | $-180,640 |
| Cash Flow From Continuing Investing Activities | $-243,019 | $-188,605 | $-169,610 | $-180,640 |
| Net Other Investing Changes | - | - | - | $-49,192 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $6,046,163 | $4,208,731 | $1,589,731 | $0 |
| Financing Cash Flow | $6,046,163 | $10,315,207 | $1,589,731 | $-44,600 |
| Cash Flow From Continuing Financing Activities | $6,046,163 | $10,315,207 | $1,589,731 | $-44,600 |
| Net Common Stock Issuance | $6,046,163 | $4,208,731 | $1,589,731 | $0 |
| Common Stock Issuance | $6,046,163 | $4,208,731 | $1,589,731 | $0 |
| Other | ||||
| End Cash Position | $1,802,123 | $6,499,885 | $1,352,102 | $5,813,218 |
| Beginning Cash Position | $6,499,885 | $1,352,102 | $5,813,218 | $10,917,797 |
| Effect Of Exchange Rate Changes | $-50,519 | $-19,816 | $0 | - |
| Changes In Cash | $-4,647,243 | $5,167,599 | $-4,461,116 | $-5,104,579 |
| Proceeds From Stock Option Exercised | $0 | $6,106,476 | $0 | $0 |
| Net Investment Purchase And Sale | $-143,267 | $0 | - | - |
| Net Intangibles Purchase And Sale | $-75,106 | $-145,591 | $-135,862 | $-131,448 |
| Purchase Of Intangibles | $-75,106 | $-145,591 | - | $-131,448 |
| Net PPE Purchase And Sale | $-24,646 | $-43,014 | $-33,748 | $-49,192 |
| Purchase Of PPE | $-24,646 | $-43,014 | $-33,748 | $-49,192 |
| Change In Working Capital | $195,576 | $106,556 | $143,264 | $-351,475 |
| Change In Other Working Capital | $-4,962 | $4,962 | - | - |
| Change In Other Current Liabilities | $-37,093 | $-33,273 | $-44,814 | $0 |
| Change In Payables And Accrued Expense | $396,637 | $826,468 | $88,492 | $45,503 |
| Change In Prepaid Assets | $55,313 | $-641,034 | $29,978 | $-257,508 |
| Change In Receivables | $-214,319 | $-50,567 | $26,539 | $-137,491 |
| Changes In Account Receivables | $-213,881 | $-35,551 | $26,539 | $-137,491 |
| Other Non Cash Items | $37,074 | $39,275 | $43,791 | $1,243,792 |
| Stock Based Compensation | $859,494 | $492,236 | $170,382 | $752,591 |
| Unrealized Gain Loss On Investment Securities | $33,714 | $69,835 | $221,693 | $764,614 |
| Asset Impairment Charge | $247,364 | $65,596 | $106,761 | $0 |
| Depreciation Amortization Depletion | $87,825 | $76,153 | $145,397 | $102,718 |
| Depreciation And Amortization | $87,825 | $76,153 | $145,397 | $102,718 |
| Net Income From Continuing Operations | $-11,911,434 | $-5,808,654 | $-6,712,525 | $-7,383,653 |
| Income Tax Paid Supplemental Data | - | $10,042 | $8,214 | $4,782 |
| Change In Payable | - | $826,468 | $88,492 | $45,503 |
| Change In Account Payable | - | $826,468 | $88,492 | $50,726 |
| Change In Inventory | - | $0 | $43,069 | $-1,979 |
| Repayment Of Debt | - | - | $0 | $-44,600 |
| Net Issuance Payments Of Debt | - | - | $0 | $-44,600 |
| Net Long Term Debt Issuance | - | - | $0 | $-44,600 |
| Long Term Debt Payments | - | - | $0 | $-44,600 |
| Depreciation | - | - | - | $141,315 |
| Sale Of Investment | - | - | - | - |
| Gain Loss On Investment Securities | - | - | - | - |
Fetched: 2026-06-24